Literature DB >> 35399177

Diagnosis and Surgical Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: A Literature Review.

Shuzo Kohno1.   

Abstract

This review aimed to highlight the characteristics and surgical treatments of tumours, and answer questions regarding the assessment of gastrointestinal neuroendocrine neoplasms (NENs) and optimal therapy. NENs comprise tumours that can produce hormones and cause a secretory syndrome. The diagnostic method and accuracy differ depending on the site of occurrence; hence, the relevant scientific society has created NEN treatment guidelines for each organ. Gastroenteric pancreatic (GEP) NENs have been unified and classified together according to the 2019 World Health Organization classification. Treatment is based on complete tumour resection, and when metastatic or primary lesions cannot be completely resected, lesions and symptoms are treated. Except for surgery for NENs, chemotherapy, molecularly targeted drugs, transarterial chemoembolization, etc., have also been confirmed as treatments. GEP NEN treatment methods will continue to advance and change because of surgery and other advances in treatment and diagnostic methods. Copyright 2022, International Institute of Anticancer Research.

Entities:  

Keywords:  Neuroendocrine neoplasms; carcinoid tumor; general surgery; guideline; neuroendocrine carcinoma; neuroendocrine tumors; review; therapeutics

Year:  2022        PMID: 35399177      PMCID: PMC8962810          DOI: 10.21873/cdp.10085

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  112 in total

Review 1.  Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.

Authors:  Zu-Yi Ma; Yuan-Feng Gong; Hong-Kai Zhuang; Zi-Xuan Zhou; Shan-Zhou Huang; Yi-Ping Zou; Bo-Wen Huang; Zhong-Hai Sun; Chuan-Zhao Zhang; Yun-Qiang Tang; Bao-Hua Hou
Journal:  World J Gastroenterol       Date:  2020-05-21       Impact factor: 5.742

Review 2.  PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).

Authors:  Halfdan Sorbye; Grace Kong; Simona Grozinsky-Glasberg
Journal:  Endocr Relat Cancer       Date:  2020-03       Impact factor: 5.678

3.  Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.

Authors:  Ding-Hui Dong; Xu-Feng Zhang; George Poultsides; Flavio Rocha; Sharon Weber; Ryan Fields; Kamran Idrees; Cliff Cho; Shishir K Maithel; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2019-09-30       Impact factor: 3.454

Review 4.  Pancreatic endocrine tumors.

Authors:  Kjell Oberg
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 5.  Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT.

Authors:  Yasemin Sanli; Ishan Garg; Asha Kandathil; Tuba Kendi; Maria J Baladron Zanetti; Serkan Kuyumcu; Rathan M Subramaniam
Journal:  AJR Am J Roentgenol       Date:  2018-07-05       Impact factor: 3.959

6.  Upfront Small Bowel Resection for Small Bowel Neuroendocrine Tumors With Synchronous Metastases: A Propensity-score Matched Comparative Population-based Analysis.

Authors:  Sean Bennett; Natalie Coburn; Calvin Law; Alyson Mahar; Haoyu Zhao; Simron Singh; Victoria Zuk; Sten Myrehaug; Vaibhav Gupta; Jordan Levy; Julie Hallet
Journal:  Ann Surg       Date:  2020-11-18       Impact factor: 13.787

7.  Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours.

Authors:  G C Nikou; K Marinou; P Thomakos; D Papageorgiou; V Sanzanidis; P Nikolaou; C Kosmidis; A Moulakakis; E Mallas
Journal:  Pancreatology       Date:  2008-09-03       Impact factor: 3.996

8.  Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study.

Authors:  Sven-Petter Haugvik; Eva Tiensuu Janson; Pia Österlund; Seppo W Langer; Ragnhild Sørum Falk; Knut Jørgen Labori; Lene Weber Vestermark; Henning Grønbæk; Ivar Prydz Gladhaug; Halfdan Sorbye
Journal:  Ann Surg Oncol       Date:  2015-12-17       Impact factor: 5.344

9.  The 2019 WHO classification of tumours of the digestive system.

Authors:  Iris D Nagtegaal; Robert D Odze; David Klimstra; Valerie Paradis; Massimo Rugge; Peter Schirmacher; Kay M Washington; Fatima Carneiro; Ian A Cree
Journal:  Histopathology       Date:  2019-11-13       Impact factor: 5.087

10.  Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Yosuke Horita; Kyoichi Kaira; Tomonori Kawasaki; Yoshiaki Mihara; Shinichi Sakuramoto; Shigeki Yamaguchi; Kojun Okamoto; Shomei Ryozawa; Yoshikatsu Kanai; Masanori Yasuda; Tetsuya Hamaguchi
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.